Atara Biotherapeutics continues to see net losses mount as it awaits news from the U.S. Food and Drug Administration, but the sale of its Thousand Oaks manufacturing facility for $100 million will help fund operations for the next two years. Atara, a South San Francisco-based immunotherapy company with its major operations in Thousand Oaks, reported…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
